US Stock MarketDetailed Quotes

Bicara Therapeutics (BCAX)

Watchlist
  • 24.010
  • +0.080+0.33%
Close Apr 17 16:00 ET
  • 24.010
  • 0.0000.00%
Post 20:01 ET
1.57BMarket Cap-9.53P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Bicara Therapeutics (BCAX) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
88.87%155.6M
54.38%41.12M
97.19%40.68M
62.12%32.02M
171.81%41.79M
106.55%82.39M
94.62%26.64M
116.45%20.63M
19.75M
15.37M
Selling and administrative expenses
62.54%30.51M
20.40%8.13M
61.65%7.7M
84.70%7.22M
123.07%7.46M
102.44%18.77M
116.13%6.75M
83.87%4.76M
--3.91M
--3.34M
-General and administrative expense
62.54%30.51M
20.40%8.13M
61.65%7.7M
84.70%7.22M
123.07%7.46M
102.44%18.77M
116.13%6.75M
83.87%4.76M
--3.91M
--3.34M
Research and development costs
96.63%125.1M
65.92%32.99M
107.86%32.98M
56.54%24.8M
185.35%34.33M
107.79%63.62M
88.25%19.88M
128.62%15.86M
--15.84M
--12.03M
Operating profit
-88.87%-155.6M
-54.38%-41.12M
-97.19%-40.68M
-62.12%-32.02M
-171.81%-41.79M
-106.55%-82.39M
-94.62%-26.64M
-116.45%-20.63M
-19.75M
-15.37M
Net non-operating interest income expense
22.56%17.87M
-35.41%3.79M
39.37%4.39M
73.34%4.68M
74.89%5.01M
1,009.67%14.58M
350.88%5.87M
24,107.69%3.15M
2.7M
2.87M
Non-operating interest income
22.56%17.87M
-35.41%3.79M
39.37%4.39M
73.34%4.68M
74.89%5.01M
1,009.67%14.58M
350.88%5.87M
24,107.69%3.15M
--2.7M
--2.87M
Other net income (expense)
Income before tax
-103.12%-137.73M
-79.74%-37.33M
-107.60%-36.29M
-60.34%-27.34M
-194.03%-36.77M
-30.45%-67.81M
-67.04%-20.77M
23.48%-17.48M
-17.05M
-12.51M
Income tax
16.04%217K
-71.51%53K
40K
52K
7,100.00%72K
3,640.00%187K
3,620.00%186K
0
0
1K
Net income
-102.88%-137.95M
-78.39%-37.39M
-107.83%-36.33M
-60.64%-27.39M
-194.58%-36.85M
-30.80%-68M
-68.46%-20.96M
23.48%-17.48M
-17.05M
-12.51M
Net income continuous Operations
-102.88%-137.95M
-78.39%-37.39M
-107.83%-36.33M
-60.64%-27.39M
-194.58%-36.85M
-30.80%-68M
-68.46%-20.96M
23.48%-17.48M
---17.05M
---12.51M
Minority interest income
Net income attributable to the parent company
-102.88%-137.95M
-78.39%-37.39M
-107.83%-36.33M
-60.64%-27.39M
-194.58%-36.85M
-30.80%-68M
-68.46%-20.96M
23.48%-17.48M
-17.05M
-12.51M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-102.88%-137.95M
-78.39%-37.39M
-107.83%-36.33M
-60.64%-27.39M
-194.58%-36.85M
-30.80%-68M
-68.46%-20.96M
23.48%-17.48M
-17.05M
-12.51M
Basic earnings per share
37.78%-2.52
-74.36%-0.68
58.13%-0.67
-51.80%-0.5
-181.40%-0.68
-164.77%-4.05
-6.54%-0.39
-138.02%-1.6
-0.3294
-0.2416
Diluted earnings per share
37.78%-2.52
-74.36%-0.68
58.13%-0.67
-51.80%-0.5
-181.40%-0.68
-164.77%-4.05
-6.54%-0.39
-138.02%-1.6
-0.3294
-0.2416
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 88.87%155.6M54.38%41.12M97.19%40.68M62.12%32.02M171.81%41.79M106.55%82.39M94.62%26.64M116.45%20.63M19.75M15.37M
Selling and administrative expenses 62.54%30.51M20.40%8.13M61.65%7.7M84.70%7.22M123.07%7.46M102.44%18.77M116.13%6.75M83.87%4.76M--3.91M--3.34M
-General and administrative expense 62.54%30.51M20.40%8.13M61.65%7.7M84.70%7.22M123.07%7.46M102.44%18.77M116.13%6.75M83.87%4.76M--3.91M--3.34M
Research and development costs 96.63%125.1M65.92%32.99M107.86%32.98M56.54%24.8M185.35%34.33M107.79%63.62M88.25%19.88M128.62%15.86M--15.84M--12.03M
Operating profit -88.87%-155.6M-54.38%-41.12M-97.19%-40.68M-62.12%-32.02M-171.81%-41.79M-106.55%-82.39M-94.62%-26.64M-116.45%-20.63M-19.75M-15.37M
Net non-operating interest income expense 22.56%17.87M-35.41%3.79M39.37%4.39M73.34%4.68M74.89%5.01M1,009.67%14.58M350.88%5.87M24,107.69%3.15M2.7M2.87M
Non-operating interest income 22.56%17.87M-35.41%3.79M39.37%4.39M73.34%4.68M74.89%5.01M1,009.67%14.58M350.88%5.87M24,107.69%3.15M--2.7M--2.87M
Other net income (expense)
Income before tax -103.12%-137.73M-79.74%-37.33M-107.60%-36.29M-60.34%-27.34M-194.03%-36.77M-30.45%-67.81M-67.04%-20.77M23.48%-17.48M-17.05M-12.51M
Income tax 16.04%217K-71.51%53K40K52K7,100.00%72K3,640.00%187K3,620.00%186K001K
Net income -102.88%-137.95M-78.39%-37.39M-107.83%-36.33M-60.64%-27.39M-194.58%-36.85M-30.80%-68M-68.46%-20.96M23.48%-17.48M-17.05M-12.51M
Net income continuous Operations -102.88%-137.95M-78.39%-37.39M-107.83%-36.33M-60.64%-27.39M-194.58%-36.85M-30.80%-68M-68.46%-20.96M23.48%-17.48M---17.05M---12.51M
Minority interest income
Net income attributable to the parent company -102.88%-137.95M-78.39%-37.39M-107.83%-36.33M-60.64%-27.39M-194.58%-36.85M-30.80%-68M-68.46%-20.96M23.48%-17.48M-17.05M-12.51M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -102.88%-137.95M-78.39%-37.39M-107.83%-36.33M-60.64%-27.39M-194.58%-36.85M-30.80%-68M-68.46%-20.96M23.48%-17.48M-17.05M-12.51M
Basic earnings per share 37.78%-2.52-74.36%-0.6858.13%-0.67-51.80%-0.5-181.40%-0.68-164.77%-4.05-6.54%-0.39-138.02%-1.6-0.3294-0.2416
Diluted earnings per share 37.78%-2.52-74.36%-0.6858.13%-0.67-51.80%-0.5-181.40%-0.68-164.77%-4.05-6.54%-0.39-138.02%-1.6-0.3294-0.2416
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -